Angiotensin-converting enzyme inhibitor helps prevent late remodeling after left ventricular aneurysm repair in rats

Circulation. 2002 Sep 24;106(12 Suppl 1):I115-9.


Background: We reported in a previous study that the initial effects of left ventricular (LV) repair (LVR) for LV aneurysm were not long lasting. Angiotensin-converting enzyme inhibitor (ACE-I) is known to attenuate remodeling after myocardial infarction, and could be effective after LVR.

Methods and results: Left ventricular aneurysms were developed in rats after left anterior descending artery ligation. Rats were divided into 3 groups: sham operation with ACE-I (lisinopril 10 mg/kg/d) (n=10; group A), LVR (by plicating the LV aneurysm) with placebo (n=8; group R), and LVR with ACE-I (n=10; group RA). LV function was evaluated by echocardiography and catheterization. Oxidative stress in the myocardium was estimated by immunohistochemistry for 8-hydroxy-2'-deoxyguanosine. One week after LVR, LV end-diastolic area was smaller and fractional area change was better in the 2 LVR groups. Four weeks after LVR, LV end-diastolic area, and fractional area change deteriorated in group R but not so much in group RA; E-max was higher in group RA (0.79+/-0.20 mm Hg/mL) than in groups A (0.25+/-0.03 mm Hg/mL; P<0.01) and group R (0.27+/-0.03 mm Hg/mL; P<0.01). Oxidative stress was much lower in the 2 ACE-I groups.

Conclusions: LVR improved LV size and systolic function only in the early phase. Adjuvant use of ACE-I was useful for preventing redilation and maintaining LV systolic function, was associated with suppressed oxidative stress, and may make LVR a more effective surgical procedure for LV aneurysm.

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Animals
  • Cardiac Catheterization
  • Chemotherapy, Adjuvant
  • Deoxyguanosine / analogs & derivatives*
  • Deoxyguanosine / analysis
  • Deoxyguanosine / immunology
  • Heart Aneurysm / drug therapy*
  • Heart Aneurysm / pathology
  • Heart Aneurysm / physiopathology
  • Heart Aneurysm / surgery
  • Hemodynamics / drug effects
  • Immunohistochemistry
  • Kinetics
  • Lisinopril / therapeutic use*
  • Male
  • Myocardium / pathology
  • Natriuretic Peptide, Brain / biosynthesis
  • Natriuretic Peptide, Brain / genetics
  • Organ Size / drug effects
  • RNA, Messenger / biosynthesis
  • Rats
  • Rats, Sprague-Dawley
  • Systole
  • Ventricular Function, Left / drug effects
  • Ventricular Remodeling / drug effects*


  • Angiotensin-Converting Enzyme Inhibitors
  • RNA, Messenger
  • Natriuretic Peptide, Brain
  • 8-Hydroxy-2'-Deoxyguanosine
  • Lisinopril
  • Deoxyguanosine